Two trials presented at the annual meeting of the American Society of Hematology (ASH) showed that treatment with the antithrombin inhibitor fitusiran reduced the bleeding rate in patients with severe hemophilia by roughly 90%, regardless of whether they had type A or B, and whether they had developed antibodies to recombinant clotting factors.

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology annual meeting, including: Actinium, Adagene, Affimed, Agios, Allogene, Annexon, Aprea, Arcellx, Astrazeneca, Autolus, Beigene, Editas, Emmaus, Epizyme, Equillium, Fate, Freeline, Gamida, GBT, Genentech, Glycomimetics, GSK, Hutchmed, I-Mab, Imara, Kite, Kura, Sutro.

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology annual meeting, including: Aleta, Allovir, Alx, Beigene, Bio-Path, Bluebird, BMS, Carsgen, Catamaran, CDR-Life, Cellectis, Celularity, Corvus, CTI, Epizyme, Forma, GBT, Genentech, Harpoon, Ichnos, IGM, Imago, Immunicum, Immunogen, Incyte, Janssen, Jazz, Kite, Loxo, Maat, Morphosys, Neoleukin, Novartis, Orca, Precision, Protagonist, Regeneron, Samsung, Sana, Schrodinger, Servier, Silence, Syndax, Tessa, Vincerx, X4.